Amphastar Pharmaceuticals (AMPH) Amortization of Deferred Charges (2021 - 2026)

Amphastar Pharmaceuticals' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 34.17% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 213.48% increase from a year earlier, with the FY2025 full-year figure at $6.5 million, up 53.52% from the prior year.
• Amortization of Deferred Charges rose to $2.1 million in Q1 2026 per AMPH's latest filing, from $1.6 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $6.7 million in Q3 2023 and bottomed at -$1.1 million in Q4 2024.
• The 5-year median for Amortization of Deferred Charges is $828000.0 (2022), against an average of $1.3 million.
• Biggest YoY gain for Amortization of Deferred Charges was 1561.02% in 2024; the steepest drop was 136.73% in 2024.
• Year by year, Amortization of Deferred Charges stood at $902000.0 in 2022, then jumped by 222.95% to $2.9 million in 2023, then plunged by 136.73% to -$1.1 million in 2024, then surged by 253.83% to $1.6 million in 2025, then surged by 30.26% to $2.1 million in 2026.
• Per Business Quant, the three latest AMPH Amortization of Deferred Charges figures stand at $2.1 million (Q1 2026), $1.6 million (Q4 2025), and $500000.0 (Q3 2025).